A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf
.
Molecular Pathways: Targeting Proteasomal Protein Degradation in Cancer
2011
Clinical Cancer Research
With the approval by the U.S. Food and Drug Administration of bortezomib for the treatment of multiple myeloma and mantle cell lymphoma, the proteasome was clinically validated as a target in oncology. The proteasome is part of a complex cellular pathway that controls the specificity and rate of degradation of the majority of proteins in the cell. The search for additional drug targets in the proteasomal pathway is ongoing. In parallel, the next generation of proteasome inhibitors, exhibiting
doi:10.1158/1078-0432.ccr-11-0853
pmid:22019514
fatcat:df6ertxzjbehnb56wdwtrdhk54